Zobrazeno 1 - 10
of 70
pro vyhledávání: '"G. Cetto"'
Autor:
F. Recchia, P. Marchei, R. Trevisonne, C. Pizza, S. Chiadò Cutin, M. Tonato, S. Del Prete, G. Vietti Ramus, C. Oliva, T. Iannone, Mario Roselli, V. Bortolussi, F. Nigro Imperiale, S. Venuta, V. Angelini, S. Cascinu, C. Volta, M. Musi, V. Guardasole, R. Ferraldeschi, L. Isa, Stefano Cascinu, F. Cognetti, M.L. Evangelista, E. Biondi, M.P. Sirgiovanni, C. Modenesi, V. Gebbia, D. Santini, E. Greco, E. Ferrazzi, M. Betti, F. Verderame, C. Bumma, G. Cicero, G. Pieri, G. Nastasi, A. Pessi, L. Patoia, S. Palazzo, M. Belli, C. Di Fonzo, Giuseppe Colucci, S. Cigolari, G. Fornarini, F. Ferraù, G. Rosati, A. Nuzzo, G. Porcile, P. Sozzi, A. Mozzicafreddo, M. Chetrì, B. Massidda, G. Luporini, A. Lembo, R. Carroccio, F. Testore, Enzo Ballatori, V. Bon-ciarelli, G. Ausili Cefaro, P. Marchetti, P. Berniolo, G. Filippelli, Enrico Cortesi, Salvatore Palazzo, A. Prosperi, G. Citone, M. Cremonesi, A. Peta, G. Rimondi, Giorgio Mustacchi, Francesco Di Costanzo, F. Marrocolo, R. Laricchiuta, R. Maurizi Enrici, D. Perrone, G. P. Iannello, Fausto Roila, A. Lavarello, L. Manzione, V. Lacava, G. Solina, P. Manente, A. Cioffi, R. Ceccherini, V. Sidoti, V. Picece, E. Recaldin, V. Tinessa, P. Giordani, M. D'Aprile, O. Bertetto, M. D'Amico, M. Serlenga, E. Vigevani, M. Mazzoli, Giovanni Mantovani, P. Marsilio, P. Rizzo, V. Mascia, G. Tonini, G. Carteni, Alberto Sobrero, B. Daniele, L. Milesi, Benedetta Ruggeri, G. Margutti, M. Botturi, M. Nicodemo, V. Silingardi, C. Iacono, A. Comandone, G. Colucci, P. Alessandroni, E. Zarra, G. Beretta, G. Reguzzoni, M. Turaz-za, L. Tonda, A. Rossi, G. Troccoli, S. Mosconi, G. Catalano, S. Bretti, T. Prantera, M. Destefanis, A. Sobrero, G. Cruciani, V. Sciacca, M. Marzola, P. Malacarne, M. Mandalà, L. Montalbetti, G. Tuveri, A Ruggiero, A. Zaniboni, G. Cetto, S. Spada, S. Barni, Roberto Labianca, C. Caroti, M.T. Ionta, C. Bressi
Publikováno v:
Tumori Journal. 91:472-476
Aims and Background Rarely are conclusions from clinical trials summarized in international consensus conferences and promptly transferred to patient care. The adjuvant therapy for colorectal cancer used in daily clinical practice in Italy is describ
Autor:
Rolando Nortilli, P. Manno, M. Pavarana, P. Bozzi, Q. Piubello, Annamaria Molino, Franco Bonetti, L. G. Cetto, Rocco Micciolo, R. Pedersini
Publikováno v:
Annals of Oncology. 11:581-586
Background It is well known that mammographic screening reduces breast cancer mortality. One possible explanation for this effect is that screening makes it possible to detect smaller breast cancers with fewer involved nodes, but another hypothesis i
Publikováno v:
Cancer. 80(12)
Studies of chemotherapy for patients with small cell lung carcinoma (SCLC) have shown that teniposide (T) may have higher activity than etoposide (E). In this randomized, controlled Phase III study, the authors compared cyclophosphamide, doxorubicin,
Autor:
D, Tummarello, F, Graziano, D, Mari, G, Cetto, F, Pasini, S, Antonio, P, Isidori, S, Gasparini
Publikováno v:
Anticancer research. 14(5B)
In this phase III, double-random study, we compared CAV-E to CAV-T combination as induction treatment (1st randomization) for SCLC. Subsequently, patients achieving a complete response (CR) were randomized again (2nd randomization) to receive mainten
Publikováno v:
Anticancer research. 11(2)
The efficacy of the serotonin antagonist ondansetron (GR38032F, Glaxo) was evaluated in the prevention of nausea and vomiting induced by combinations containing cyclophosphamide (CTX) greater than or equal to 600 mg/m2 IV day. At their first treatmen
Autor:
Sergio Bracarda, Fausto Roila, M A Bella, G. Cetto, A. Del Favero, Maurizio Tonato, M. Marangolo, D. Donati
Publikováno v:
Clinical oncology (Royal College of Radiologists (Great Britain)). 2(5)
Sixty five chemotherapy naive patients receiving cisplatin (50–120 mg/m 2 ) containing chemotherapy participated in an evaluation of ondansetron, a 5-HT 3 receptor antagonist, in the prophylaxis of acute and delayed nausea and emesis. Ondansetron w
Autor:
F. Pasini, G. De Manzoni, A. Grandinetti, C. Pedrazzani, C. Griso, T. Sava, A. Minicozzi, E. Durante, A. Bonetti, S. Maluta, G. Cetto
Publikováno v:
Journal of Clinical Oncology. 24:4057-4057
4057 Background: The achievement of pathological complete response (pCR) is deemed essential to improve survival in EC. In a phase I study (Pasini et al, Ann Oncol 16; 1123, 2005) we demonstrated the feasibility of a novel protocol of neoadjuvant che
Publikováno v:
Haematologica. 61(3)
Publikováno v:
Haematologica. 63(1)
Publikováno v:
Haematologica. 66(4)